Arecor Therapeutics plc
("Arecor" or the "Company")
Posting of Annual Report and Notice of AGM
Cambridge, UK, 28 April 2026: Arecor Therapeutics plc (AIM: AREC), a clinical stage biotech company developing superior therapeutics that can reduce treatment burden and improve outcomes for people living with diabetes, obesity and other cardiometabolic diseases, has today published and posted to shareholders its Annual Report and Accounts for the year ended 31 December 2025.
The Company has also shared the Notice of the Annual General Meeting ("AGM") which will be held on Thursday, 28 May at 9.30am BST at the offices of Covington & Burling LLP, 22 Bishopsgate, London EC2N 4BQ.
In order to ensure that shareholders are able to follow the proceedings of the AGM without attending in person, the Company will provide access online via the Investor Meet Company platform.
Please note that shareholders will not be able to vote online at the AGM via the platform and are therefore requested to submit their votes via proxy, as early as possible. Shareholders that wish to attend the AGM remotely should register for the event in advance by emailing maggie.mcconnell@arecor.com
The Annual Report and Accounts and Notice of AGM are also now available to view and download from the Company's website at https://arecor.com/investor-centre/shareholder-information/
-ENDS-
For more information, please contact:
|
Arecor Therapeutics plc |
+44 (0) 1223 426060 info@arecor.com |
|
Singer Capital Markets Advisory LLP |
+44 (0) 20 7496 3000 |
|
Vigo Consulting (Financial Communications) |
+44 (0) 20 7390 0230 arecor@vigoconsulting.com |
|
Vida Strategic Partners (US Investor Relations) Stephanie Diaz |
+1 (415) 675-7401 sdiaz@vidasp.com |
Notes to Editors
About Arecor
Arecor Therapeutics plc (AIM: AREC) is a clinical-stage biotech company developing superior therapeutics that can reduce treatment burden and improve outcomes for people living with diabetes, obesity and other cardiometabolic diseases.
Lead product, AT278, is the only ultra-concentrated (500U/mL) ultra-rapid-acting insulin in development. Arecor has signed an initial strategic partnership with Sequel Med Tech, a leading automated insulin delivery (AID) system company to co-develop AT278 in combination with Sequel's twiist™ AID system. Clinically de-risked, AT278 is designed to transform AID systems, addressing a multi-billion dollar diabetes market. Arecor is also developing a novel oral delivery platform for peptides with GLP-1 receptor agonists its first validation target.
The Company is listed on AIM (AIM: AREC) and is based in Cambridge, UK. For further details please see www.arecor.com.
Arecor® and Arestat® are registered trademarks of Arecor Limited.